SciELO - Scientific Electronic Library Online

vol.69 número1Pancreatitis agudaEstudio retrospectivo del efecto del furoato de mometasona al 0.1% en el tratamiento no quirúrgico de fimosis y adherencias prepuciales en niños mexicanos índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados



Links relacionados

  • Não possue artigos similaresSimilares em SciELO


Boletín médico del Hospital Infantil de México

versão impressa ISSN 1665-1146


JASSO-GUTIERREZ, Luis et al. Estimation of chemotherapy costs applying the full protocol of children with acute lymphoblastic leukemia or Hodgkin's lymphoma: case study. Bol. Med. Hosp. Infant. Mex. [online]. 2012, vol.69, n.1, pp. 11-23. ISSN 1665-1146.

Introduction. Of all types of cancer, acute lymphoblastic leukemia (ALL) constitutes the most common type of cancer during the pediatric age. Lymphomas occupy third place. Treatment costs of ALL and Hodgkin lymphoma (HL) in children are high. The aim of the study was to calculate total unit costs of drugs in cancer children with ALL and HL using the current protocols in the Hospital Infantil de Mexico Federico Gomez (HIMFG). The costs were estimated by risk stratification for ALL patients and according to tumor stage for HL. Methods. Calculations were performed using a specific methodology and using the complete protocols of ALL and HL in the different strata for a child weighing 20 kg with a height of 115 cm and 30 kg with a height of 135 cm. Results. The total unit cost in standard-risk ALL was 71,655.00 MXN (~$5,430 USD at the time of publication) in the patient weighing 20 kg and 95,825.90 MXN (~$7,250 USD) for the patient weighing 30 kg. In HL, the cost of stage IB-IIB was 39,342.16 MXN (~$3,000 USD) in the child weighing 20 kg and 52,620.14 MXN (~$4,000 USD) in the child weighing 30 kg. Costs for treating patient in stages III-IV corresponded to 41,469.46 MXN (~$3,150 USD) and 55,465.39 MXN (~$4,200.00), respectively. Conclusions. There were both differences and advantages in the HIMFG protocol for ALL. Comparing costs with costs in other countries showed similar results when only the unit costs were evaluated.

Palavras-chave : acute lymphoblastic leukemia; Hodgkin lymphoma; chemotherapy; costs; cancer drugs.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License